At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine
In Brief
A clinical study evaluating fludeoxyglucose F 18, positron emission tomography, and 5 other interventions for Bone Metastases and 6 related conditions. Active but no longer recruiting, targeting 10 participants across 1 site.
Detailed Summary
This pilot clinical trial studies how well copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET) works in predicting response to treatment with ado-trastuzumab emtansine in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread to other places in the body. Copper Cu 64-DOTA-trastuzumab is a chemotherapy drug (trastuzumab) attached to a radioactive substance. Diagnostic procedures using PET may allow scanners to take pictures of where the drug travels in the body and may help doctors identify which patients may benefit from treatment with ado-trastuzumab emtansine.
Study Details
Timeline
Interventions
Undergo fludeoxyglucose F 18 PET/CT
Undergo fludeoxyglucose F 18 PET/CT
Undergo fludeoxyglucose F 18 PET/CT
Given IV
Given IV
Undergo copper Cu-DOTA-trastuzumab PET
Given IV
Correlative studies